it was established in 2000 to translate the work of uk medical research council mrc research scientists today lifearc provides intellectual property identification protection and commercialisation technology development diagnostic development early stage drug discovery and antibody humanization services for the mrc academia biotechnology and pharmaceutical organisations and charities aiming to move promising medical research forward into viable and accessible patient treatments profits from lifearc s activities are reinvested into further research lifearc started as the medical research council liaison office in 1984 and in 1986 the mrc collaborative centre a laboratory based technology transfer function was founded in 1993 the liaison office became mrc s technology transfer group responsible for office based patenting and licensing the organisation was set up as a charity and a company limited by guarantee in 2000 to incorporate patenting licensing and research functions on 15 june 2017 it officially became lifearc lifearc has humanised a number of antibodies on behalf of other organisations four of these tysabri biogen idec elan actemra hoffmann la roche chugai entyvio millenium pharma takeda and keytruda merck msd are now on the market in 2010 lifearc signed a deal with the drug company astrazeneca to share chemical compounds to help